Alnylam Pharmaceuticals, Inc.
Serpina1 iRNA compositions and methods of use thereof
Last updated:
Abstract:
The invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the Serpina1 gene, and methods of using such RNAi agents to inhibit expression of Serpina1 and methods of treating subjects having a Serpina1 associated disease, such as a liver disorder.
Status:
Grant
Type:
Utility
Filling date:
14 Jun 2018
Issue date:
16 Feb 2021